Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05750290

CKD-702 Plus Irinotecan in Gastric Cancer

Conditions: Gastric Cancer

Sex: All

Ages: 19 Years – N/A

Phase: PHASE2

Enrollment: 40

Sponsor: National Cancer Center, Korea

Location: Korea, Republic of

Summary

CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.

Eligibility Criteria

Inclusion Criteria:Failed 2 or more lines of chemotherapyTumor overexpressing either MET or EGFRMeasurable lesionExclusion Criteria:Prior treatment with anti-MET/EGFR bispecific antibody

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05750290). StuddyBuddy aggregates publicly available trial information.